Vivek Garipalli bought $930K of Clover Health Investments (CLOV)
Executed Aug 7 2025, disclosed Aug 8 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Aug 8 2025), the stock returned +24.0% (delay-adjusted); from the execution session (Aug 7 2025), +20.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Vivek Garipalli (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Clover Health Investments, Corp. (CLOV). Across 1 priced purchase filing, the average 21-session return was +20.1% from execution and +24.0% from disclosure (delay-adjusted; derived). The largest single filing was $930K of CLOV (415,000 sh × $2.24, as filed), executed Aug 7 2025.
Healthcare · Clover Health Investments, Corp. provides medicare advantage plans in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→